Featured Trial

A Clinical Study That Will Measure How Well SEP‑363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Study Identifier:
SEP361-226
ClinicalTrials.gov Identifier:
NCT05729373
EudraCT Identifier:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
N/A
Study Contact Information:
N/A
Active, Not Recruiting
Subscribe to updatesSee if you Qualify
Type
Interventional
Phase
Phase 2/Phase 3
Estimated Enrollment
434
Trial Dates
Mar 2023 - Sep 2025
Study Drug
  • Drug: SEP-363856
  • Drug: Placebo
    • Therapeutic Area
  • Anxiety

    • Trial Locations

    Location
    Status
    Location
    University of Alabama at Birmingham
    Huntsville, Alabama, United States, 35801
    Status
    N/A
    Location
    IMA Clinical Research Phoenix
    Phoenix, Arizona, United States, 85012
    Status
    N/A
    Location
    ProScience Research Group
    Culver City, California, United States, 90230
    Status
    N/A
    Location
    Excell Research, Inc.
    Oceanside, California, United States, 92056
    Status
    N/A
    Location
    Anderson Clinical Research
    Redlands, California, United States, 92374
    Status
    N/A
    Location
    California Neuroscience Research, LLC
    Sherman, California, United States, 91403
    Status
    N/A
    Go to page
    © 2025 Otsuka America Pharmaceutical, Inc
    All rights reserved.

    July 2025 01US25EUC0279

    Requirements information
    Inclusion criteria
    • (list is not all inclusive)
    • Male or female subject between 18 to 65 years of age.
    • Subject meets DSM-5 criteria for a diagnosis of Generalized Anxiety Disorder.
    • Subject must be willing and able to comply with the study procedures and visit schedule and must be able to understand and follow verbal and written instructions.
    Exclusion criteria
    • (list is not all inclusive)
    • Subject has DSM-5-based diagnosis of any disorder other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
    • Subjects who report an inadequate response to more than 3 antidepressant treatments
    • Subject is at significant risk of harming self or others based on Investigator's judgment.
    • Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
    • Female subject who is pregnant, lactating, or plans to get pregnant during the study.

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone 800-562-3974